Drug News
-
Everest Medicines’ Nefecon® Advances Toward Approval for IgA Nephropathy Treatment in Taiwan
Shanghai-based biopharmaceutical company Everest Medicines has announced that its New Drug Application (NDA) for Nefecon® has been accepted for review…
Read More » -
Lead Poisoning Nightmare: Tainted Fruit Puree Pouches Cause 251 Cases Across 34 States
A startling surge in lead poisoning cases linked to contaminated fruit puree pouches has reached a staggering 251 reported cases…
Read More » -
FDA Issues New Guidance to Tackle Benzene Levels in Drug Products
In a significant move, the U.S. Food and Drug Administration (FDA) has issued new guidance aimed at aiding drug manufacturers…
Read More » -
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene
Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), has initiated a voluntary recall of one lot of Americaine® 20%…
Read More » -
Pfizer’s Hospira, Inc. Initiates Voluntary Recall of Bleomycin for Injection Due to Glass Particulate Contamination
Pfizer’s Hospira, Inc., a leading pharmaceutical company, has issued a voluntary recall of one lot of Bleomycin for Injection, USP…
Read More » -
Generic Drugmaker Stada has Spun off Russian Business
In recent news, the generic drugmaker Stada has reportedly separated its Russian business, establishing a distinct entity named Nizhpharm, as…
Read More » -
Use of Unapproved Fat-Dissolving Injections Poses Serious Health Risks FDA Warns
In a recent announcement, the Food and Drug Administration (FDA) has issued a stern warning about the potential dangers associated…
Read More » -
FDA Approves Safety Labeling Changes for Opioid Pain Medicines
The Food and Drug Administration (FDA) has officially granted final approval and implemented mandatory safety labeling updates for opioid analgesic…
Read More » -
Jazz Pharmaceuticals Faces Setback as PTSD Drug Fails Mid-Stage Trial
Jazz Pharmaceuticals (JAZZ.O) encountered a setback as its investigational drug, JZP150, designed for the treatment of post-traumatic stress disorder (PTSD),…
Read More » -
Bristol Myers Acquire Karuna Therapeutics in $14 Billion Megadeal
In a strategic move, Bristol Myers Squibb has announced a groundbreaking acquisition of Karuna Therapeutics for a staggering $14 billion,…
Read More »